Sanofi, Google team up in search of new treatments, marketing solutions

fiercepharma | June 18, 2019

A few months ago, Sanofi tapped its chief medical officer Ameet Nathwani, M.D., to spearhead a digital revolution at the company. And he’s bringing in the big guns to help. The French drugmaker has joined forces with Google to create a new virtual innovation lab, where the partners will marry Google’s technology and analytics expertise with Sanofi’s data to bring deeper understanding of diseases and patients’ experience, they said Tuesday. The lab will work on both the scientific and commercial sides in search of both more personalized approaches to treatment and digital technologies that can help improve outcomes. “We aspire to give people more control over their health and accelerate the discovery of new therapies,” Nathwani said in a statement. And that’s not all. Sanofi will also use Google’s digital prowess to improve its own operations and infrastructure. For one, the pair will deploy artificial intelligence to help forecast sales and optimize marketing and supply chain activities. “Using AI will take into account real-time information as well as geographic, logistic and manufacturing constraints to help the accuracy of these complex activities,” the companies said. Sanofi will also be moving some of its existing business to the Google Cloud platform, a transition it says will cut costs.

Spotlight

Marcopolis.net Video Interview with Dr. A. Borhan El-Din Ismail, Chairman and Executive Director of EIPICO (Egyptian International Pharmaceutical Industries Company).

Spotlight

Marcopolis.net Video Interview with Dr. A. Borhan El-Din Ismail, Chairman and Executive Director of EIPICO (Egyptian International Pharmaceutical Industries Company).

Related News

BUSINESS INSIGHTS

Acurx Pharmaceuticals to Join the Russell Microcap Index®

Acurx Pharmaceuticals, Inc. | September 06, 2021

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company is set to join the Russell Microcap® Index when the market opens on September 20, 2021, according to a preliminary list of additions posted on September 1, 2021. Membership in the Russell Microcap Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective, market-capitalization rankings, and style attributes. "Inclusion in the Russell Microcap Index reflects the ongoing achievement of our previously stated drug development objectives for our pipeline of DNA polymerase IIIC inhibitors, and the fact that, if approved, we would bring to market the first of a new class of antibiotics in over 30 years," said David P. Luci, President and CEO of Acurx. "Inclusion in the Index benefits our Company and stockholders by elevating our visibility within the global investment community. We look forward to continuing our progress towards completing the clinical development program for ibezapolstat, our lead antibiotic candidate targeting the treatment of C. difficile Infection and delivering on several key milestone catalysts through 2021 and 2022," concluded Luci. Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider. About FTSE Russell FTSE Russell is a global index leader that provides innovative benchmarking, analytics, and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering 98% of the investable market globally. FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately $17.9 trillion is currently benchmarked to FTSE Russell indexes. For over 30 years, leading asset owners, asset managers, ETF providers and investment banks have chosen FTSE Russell indexes to benchmark their investment performance and create ETFs, structured products, and index-based derivatives. A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering. FTSE Russell is wholly owned by London Stock Exchange Group. About Acurx Pharmaceuticals, Inc. Acurx Pharmaceuticals is a clinical stage biopharmaceutical company focused on developing new antibiotics for difficult to treat infections. The Company's approach is to develop antibiotic candidates that target the DNA polymerase IIIC enzyme and its R&D pipeline includes antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP).

Read More

PHARMA TECH

PFIZER AND BIONTECH ANNOUNCE VACCINE CANDIDATE AGAINST COVID-19

Pfizer | November 10, 2020

Pfizer Inc.and BioNTech SE today reported their mRNA-based antibody up-and-comer, BNT162b2, against SARS-CoV-2 has exhibited proof of adequacy against COVID-19 in members without earlier proof of SARS-CoV-2 contamination, in view of the principal break viability examination led on November 8, 2020 by an outer, free Data Monitoring Committee (DMC) from the Phase 3 clinical investigation. After conversation with the FDA, the organizations as of late chosen to drop the 32-case between time examination and lead the primary interval investigation at least 62 cases. Upon the finish of those conversations, the evaluable case check arrived at 94 and the DMC played out its first examination on all cases. The case split between inoculated people and the individuals who got the fake treatment shows an immunization viability rate above 90%, at seven days after the subsequent portion. This implies that insurance is accomplished 28 days after the inception of the immunization, which comprises of a 2-portion plan. As the investigation proceeds, the last antibody adequacy rate may shift. The DMC has not detailed any genuine security concerns and prescribes that the examination keeps on gathering extra wellbeing and viability information as arranged. The information will be talked about with administrative specialists around the world. “Today is a great day for science and humanity. The first set of results from our Phase 3 COVID-19 vaccine trial provides the initial evidence of our vaccine’s ability to prevent COVID-19,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “We are reaching this critical milestone in our vaccine development program at a time when the world needs it most with infection rates setting new records, hospitals nearing over-capacity and economies struggling to reopen. With today’s news, we are a significant step closer to providing people around the world with a much-needed breakthrough to help bring an end to this global health crisis. We look forward to sharing additional efficacy and safety data generated from thousands of participants in the coming weeks.” “I want to thank the thousands of people who volunteered to participate in the clinical trial, our academic collaborators and investigators at the study sites, and our colleagues and collaborators around the world who are dedicating their time to this crucial endeavor,” added Bourla. “We could not have come this far without the tremendous commitment of everyone involved.” “The first interim analysis of our global Phase 3 study provides evidence that a vaccine may effectively prevent COVID-19. This is a victory for innovation, science and a global collaborative effort,” said Prof. Ugur Sahin, BioNTech Co-founder and CEO. “When we embarked on this journey 10 months ago this is what we aspired to achieve. Especially today, while we are all in the midst of a second wave and many of us in lockdown, we appreciate even more how important this milestone is on our path towards ending this pandemic and for all of us to regain a sense of normality. We will continue to collect further data as the trial continues to enroll for a final analysis planned when a total of 164 confirmed COVID-19 cases have accrued. I would like to thank everyone who has contributed to make this important achievement possible.” The Phase 3 clinical preliminary of BNT162b2 started on July 27 and has selected 43,538 members to date, 38,955 of whom have gotten a second portion of the immunization competitor as of November 8, 2020. Roughly 42% of worldwide members and 30% of U.S. members have racially and ethnically assorted foundations. The preliminary is proceeding to select and is relied upon to proceed through the last examination when an aggregate of 164 affirmed COVID-19 cases have gathered. The investigation likewise will assess the potential for the antibody possibility to give insurance against COVID-19 in the individuals who have had earlier presentation to SARS-CoV-2, just as immunization avoidance against serious COVID-19 infection. Notwithstanding the essential adequacy endpoints assessing affirmed COVID-19 cases accumulating from seven days after the subsequent portion, the last investigation currently will incorporate, with the endorsement of the FDA, new auxiliary endpoints assessing viability dependent on cases building 14 days after the subsequent portion also. The organizations accept that the expansion of these optional endpoints will help adjust information over all COVID-19 antibody reads and consider cross-preliminary learnings and correlations between these novel immunization stages. Pfizer and BioNTech are proceeding to gather security information and presently gauge that a middle of two months of wellbeing information following the second (and last) portion of the antibody up-and-comer – the measure of security information indicated by the FDA in its direction for likely Emergency Use Authorization – will be accessible by the third seven day stretch of November. Moreover, members will keep on being checked for long haul assurance and wellbeing for an extra two years after their subsequent portion. Alongside the viability information created from the clinical preliminary, Pfizer and BioNTech are attempting to set up the important wellbeing and assembling information to submit to the FDA to exhibit the security and nature of the antibody item delivered. In view of gracefully projections, we hope to flexibly internationally up to 50 million antibody portions in 2020 and fabricate up to 1.3 billion dosages in 2021. Pfizer and BioNTech plan to submit information from the full Phase 3 preliminary for logical friend survey distribution. About Pfizer: Breakthroughs That Change Patients’ Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. About BioNTech Biopharmaceutical New Technologies is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The Company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.

Read More

PHARMACY MARKET

KEEP, The Modern Medicine Cabinet, Announces Partnership with McKesson Canada

KEEP Labs Inc. | January 28, 2022

KEEP Labs, the Modern Medicine Cabinet and KARE by KEEP Adherence Platform developers, are pleased to announce a partnership with McKesson Canada to provide a novel solution for Canadians taking specialty medications. A majority of healthcare activities occur in the home, making it a critical place to monitor, engage and support patients. KEEP's state of the art technology and intuitive design allows McKesson Canada to provide an award-winning adherence platform that supports all dosage forms, from oral to injectable therapies. This partnership extends the reach of McKesson Canada's patient engagement capabilities, allowing them to gain greater insight into how to best support patients in real-time. KEEP and McKesson Canada are building the patient experience of the future. Despite notable advancements in new treatment options, adherence rates remain stagnant. Patient support programs have an opportunity to expand their services to drive adherence, capture real world evidence (RWE) and utilize new data sources to intelligently guide which patients can benefit most from specific interventions. "A key function of KEEP is removing friction throughout the entire patient journey and passively capturing daily dosing events through automation in real-time, rather than relying on patients to manually input when doses are taken. When we have full visibility to the last and most important mile of the therapy journey, we have the best opportunity to intervene in a proactive and meaningful way. We're helping to enable the industry to transition from retrospective monthly data points to real-time and actionable intervention capabilities." Jeff Wandzura, RPh, CEO of KEEP Labs KEEP has built an integrated technology ecosystem to support providers with the data they need to make informed decisions. Patient support program providers are confronting the complexity of integrating disparate systems to deliver actionable intelligence to all stakeholders. McKesson Canada's commitment to providing an industry-leading technology stack starts by ensuring that innovative partners, like KEEP, are enhancing and complementing existing technologies through seamless integration. The ability to intervene in real-time via nurse outreach, educational content or behavioural nudges that are configured on a program and patient archetype specific basis allows McKesson Canada to personalize the experience for each patient. These learnings are continually refined over the course of the program (using real world data), providing a first-of-its-kind data set with outcomes reported to partner organizations and members of the care team. ABOUT KEEP LABS KEEP Labs is a Canadian tech company founded by two dads who were looking for a smart way to store prescription medication at home. KEEP Lab's introductory product, KEEP, is a TIME Best Invention of 2020 and CES 2020 Innovation Honoree. KARE by KEEP is the first medication adherence and analytics platform for global life sciences companies, patient support programs and pharmacy networks that integrates both hardware and software for all dosage forms, providing deeper insight into the patient journey at home.

Read More